Bemotrizinol Is Now FDA-Approved: What It Means for Your Sunscreen

The Day American Sunscreen Changed

On June 9, 2026, the U.S. Food and Drug Administration approved bemotrizinol, marketed under the brand name PARSOL Shield, as a new active ingredient for sunscreens sold in the United States.

This is not a minor regulatory footnote. It is the first new sunscreen active ingredient added to the U.S. over-the-counter sunscreen monograph since the late 1990s. For anyone who cares about skin health, sun protection, photoaging, pigmentation, or skin cancer prevention, this is genuinely significant news.

As a board-certified dermatologist and someone who has advocated for better sunscreen access on Capitol Hill, I want to give you a clear, clinical explanation of what bemotrizinol is, why it matters, what the approval timeline means for products on store shelves, and most importantly, what you should do about your sunscreen routine right now.

What Is Bemotrizinol?

Bemotrizinol is a chemical UV filter that absorbs both UVA and UVB radiation, making it a broad-spectrum photoprotective ingredient. It is also known as BEMT, Tinosorb S, or Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine.

It has been used safely in sunscreens in Europe, Australia, and many other countries for decades. In Europe, it has been approved since 2000. The rest of the world has had access to this ingredient for a generation. Americans did not, until now.

One of bemotrizinol’s most important properties is its exceptional photostability. Unlike avobenzone, the most commonly used UVA filter in many American chemical sunscreens, bemotrizinol is highly stable when exposed to sunlight. Avobenzone can degrade with UV exposure unless it is properly stabilized by other ingredients. Bemotrizinol holds up well under UV exposure and can also help improve the performance of multi-filter sunscreen formulations.

Another advantage is that bemotrizinol is a large molecule with very low water solubility and very low systemic absorption. This is relevant because some patients have concerns about chemical sunscreen filters being absorbed into the bloodstream. Laboratory data have also been reassuring regarding estrogenic activity, which matters in the broader discussion around endocrine disruption and sunscreen ingredients.

Why Did This Take So Long?

Sunscreens in the United States are regulated as over-the-counter drugs, not cosmetics, as they are in much of the rest of the world. The FDA’s framework for evaluating new OTC sunscreen ingredients had been slow for decades, making it difficult for manufacturers to bring newer UV filters to the U.S. market.

The Sunscreen Innovation Act of 2014 was intended to help move this process forward, but progress remained slow. More recent updates to the OTC monograph pathway helped create a clearer process for reviewing sunscreen active ingredients.

DSM-Firmenich, the manufacturer of PARSOL Shield, submitted an OTC Monograph Order Request in 2024 after completing additional safety studies requested by the FDA. A proposed order was issued in December 2025, followed by a public comment period. The final approval came on June 9, 2026.

This approval matters for every American, but it is especially meaningful for patients with skin of color. Chemical UV filters tend to be more cosmetically elegant. They usually spread easily, do not leave the same white cast as many mineral sunscreens, and can blend more comfortably into a wider range of skin tones.

The limited filter options available to U.S. formulators have made it harder to create high-SPF, cosmetically elegant sunscreens with strong UVA coverage. Bemotrizinol changes that equation.

What This Means for UVA Protection

This is the part of the approval that matters most clinically.

Americans have long had fewer options for strong UVA protection compared with consumers in Europe, Japan, and Korea. UVA radiation, which includes wavelengths from about 320 to 400 nanometers, penetrates deeper into the skin than UVB. It contributes to photoaging, pigmentation disorders like melasma, immune suppression, and skin cancer risk.

SPF mainly measures protection against UVB, the rays most responsible for sunburn. SPF does not tell you the full story about UVA protection.

In Europe, sunscreens are expected to meet a UVA protection standard where the UVA protection factor is at least one-third of the labeled SPF. Many U.S. sunscreens do not meet this same benchmark.

Adding bemotrizinol to the approved U.S. filter list gives formulators a powerful tool to help close this UVA protection gap. Bemotrizinol has absorption peaks at approximately 310 nm in the UVB range and 340 nm in the UVA range, helping cover important parts of the ultraviolet spectrum.

When Will You Be Able to Buy Bemotrizinol Sunscreens?

The FDA final order takes effect on August 9, 2026. DSM Nutritional Products LLC, part of dsm-firmenich, has an 18-month exclusivity period for this ingredient in the U.S. market, including its licensees, assignees, or successors. After that period, other manufacturers may be able to use it as well.

Bemotrizinol is approved for use in adults and children 6 months and older at concentrations up to 6%.

Practically speaking, expect the first bemotrizinol-containing U.S. sunscreens to appear in late 2026 or 2027.

Products already sold internationally, including some popular Korean and European sunscreens, may contain bemotrizinol under the name BEMT or Tinosorb S. However, U.S.-sold versions of those products may have different formulations to comply with FDA rules. Watch for label updates and look for names like bemotrizinol, BEMT, Tinosorb S, or PARSOL Shield.

What Should You Do About Your Sunscreen Right Now?

The approval of bemotrizinol does not mean you should stop using sunscreen while waiting for new products. The sunscreen habits you build now are still the most important thing.

Continue using a broad-spectrum SPF 30 or higher sunscreen every day. If you are already using a tinted mineral sunscreen with iron oxides for visible light protection, especially if you have melasma or skin of color, keep using it.

When bemotrizinol sunscreens become available, they are worth trying, particularly if you have struggled with the texture or white cast of mineral sunscreens, or if you have found current U.S. chemical sunscreens irritating or cosmetically difficult to wear.

Patients with skin of color who have found it difficult to find cosmetically acceptable broad-spectrum sunscreens should watch this space closely. In my view, the approval of bemotrizinol is one of the most meaningful advances in photoprotection access in a generation.

The Bottom Line

Bemotrizinol is not just another sunscreen ingredient. It represents a major step forward for American sun protection.

It offers broad-spectrum UVA and UVB protection, strong photostability, very low systemic absorption, and the potential for more elegant sunscreen formulas that people may actually want to use every day.

For now, keep wearing your current broad-spectrum SPF 30 or higher sunscreen. When bemotrizinol products arrive in the U.S., they may offer a meaningful new option, especially for patients looking for stronger UVA protection, better texture, and less white cast.

FAQ

Q: What is bemotrizinol?

A: Bemotrizinol is a broad-spectrum chemical sunscreen filter that helps protect against both UVA and UVB radiation. It is also known as BEMT, Tinosorb S, or PARSOL Shield.

Q: Is bemotrizinol FDA-approved?

A: Yes. The FDA approved bemotrizinol on June 9, 2026, as a permitted active ingredient in over-the-counter sunscreens sold in the United States.

Q: Why is bemotrizinol important?

A: Bemotrizinol is highly photostable, offers broad-spectrum UV protection, and may help improve UVA protection in U.S. sunscreen formulations. It also has very low systemic absorption.

Q: Is bemotrizinol the same as Tinosorb S?

A: Yes. Bemotrizinol is commonly known internationally as Tinosorb S. In the U.S., it is also being marketed as PARSOL Shield.

Q: When will bemotrizinol sunscreens be available in the U.S.?

A: The FDA final order takes effect on August 9, 2026. The first U.S. sunscreens containing bemotrizinol are expected in late 2026 or 2027.

Should I wait for bemotrizinol before using sunscreen?

No. Continue using a broad-spectrum SPF 30 or higher sunscreen every day. Bemotrizinol is exciting, but your current sunscreen routine still matters.

Is bemotrizinol good for skin of color?

Bemotrizinol may help make U.S. sunscreens more cosmetically elegant, with less white cast than many mineral sunscreens. This may be especially helpful for patients with deeper skin tones who have struggled to find sunscreens they enjoy using consistently.

Updated June 2026